Xipamide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Oedema Initial: 40 mg/day in the morning, reduced to 20 mg/day if needed. Max: 80 mg/day. HTN 20 mg/day in the morning.
Dosage Details
Oral
Hypertension
Adult: 20 mg daily as a single dose in the morning.

Oral
Oedema
Adult: Initially, 40 mg daily in the morning, reduced to 20 mg daily according to response. Max: 80 mg daily.
Renal Impairment
Severe: Avoid.
Hepatic Impairment
Caution in use.
Reconstitution
Oral:
Oedema: Ref: See PI.
Contraindications
Hypersensitivity to sulphonamide. Untreated Addison's disease. Severe renal failure; severe electrolyte deficiency; precomatose states associated with cirrhosis; lactation.
Special Precautions
Pregnancy; elderly. Prostatic hypertrophy; renal or hepatic impairment; hypovolaemia; DM; hyperuricaemia; severe coronary or cerebral arteriosclerosis.
Adverse Reactions
GI disturbances; hypokalaemia; hyperuricaemia; nocturia, dizziness; impaired glucose metabolism.
Overdosage
Symptoms: Hypotension, electrolyte and metabolic disturbances. Management: Reduce further absorption by gastric lavage or induced emesis. Treatment is supportive with BP maintenance and correction of electrolyte imbalances.
Drug Interactions
Antihypertensives enhance BP-lowering effects of xipamide. Increased risk of hypokalaemia with amphotericin B, carbenoxolone.
Potentially Fatal: Propensity to cause hypokalaemia can increase risk of digitalis toxicity.
Action
Description: Xipamide is structurally related to indapamide and exerts its diuretic effect at the distal section of the nephron.
Onset: 1-2 hr
Duration: 12 hr
Pharmacokinetics:
Absorption: Rapid and well absorbed from GI tract. Peak plasma concentration: 1-2 hr.
Distribution: Protein binding: 99%.
Excretion: Excreted in urine as unchanged and glucuronide metabolite. Plasma half life: 5-8 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Xipamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in